Nuvessa

Pouchitis, Liver Abscess, Amebic, Lung Abscess + 53 more

Treatment

41 FDA approvals

20 Active Studies for Nuvessa

What is Nuvessa

Metronidazole

The Generic name of this drug

Treatment Summary

Metronidazole is an antibiotic used to treat a variety of bacterial and parasitic infections. It is most commonly used to treat infections of the gastrointestinal tract, trichomoniasis, giardiasis, and amebiasis. Metronidazole is available in several forms including capsules, tablets, topical applications, and suppositories. It has been used as an antibiotic for many years and is known for its broad range of uses.

Flagyl

is the brand name

Nuvessa Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Flagyl

Metronidazole

1963

449

Approved as Treatment by the FDA

Metronidazole, commonly known as Flagyl, is approved by the FDA for 41 uses including Bone and Joint Infections and Abscess .

Bone and Joint Infections

Abscess

Liver Abscess

Communicable Diseases

Osteomyelitis

Bacterial Endocarditis

Helicobacter Pylori Infection

Used to treat Helicobacter Pylori Infection in combination with Bismuth subsalicylate

Abdominal Abscess

Abdominal Infection

Skin and skin structure infections

Gynaecological infection

Lung Abscess

Endometritis

Central Nervous System Bacterial Infections

Bacterial Meningitis

Pneumonia

intra-abdominal bacterial infections

hepatic abscess

Tubo-ovarian abscess

Lung Abscess

Curling Ulcer

Used to treat Duodenal Ulcer in combination with Bismuth subsalicylate

Lower respiratory tract infection bacterial

Bacterial Septicemia

Bacteria, Anaerobic

Bacterial Infections

Duodenal Ulcer

Used to treat Duodenal Ulcer in combination with Bismuth subsalicylate

Meningitis

Abscess, Intra-Abdominal

Empyema

asymptomatic Trichomoniasis

Exposure via partner

Endomyometritis

Bacterial Peritonitis

Central Nervous System Bacterial Infections

Empyema

Trichomonas Infections

Endometritis

Endometritis

Bacteria

Endocarditis, Bacterial

Communicable Diseases

Effectiveness

How Nuvessa Affects Patients

Metronidazole is a medication used to treat amebiasis, trichomoniasis, and giardiasis. It has antibacterial and antiprotozoal properties and is effective against certain anaerobic bacteria. However, it does not work against most other types of bacteria or fungi. Metronidazole can cause nerve damage, convulsions, and numbness, especially when taken in high doses. It has also been found to be carcinogenic in mice and rats, though the effect on humans is unclear. It is important to only take metronidazole when necessary and only for its approved indications.

How Nuvessa works in the body

Metronidazole is used to target anaerobic bacteria and protozoa. It does this by entering the cells of these organisms and blocking their ability to make DNA. Metronidazole is reduced in the cells, producing toxic metabolites that damage the DNA and make it difficult for the organisms to replicate.

When to interrupt dosage

The measure of Nuvessa is dependent upon the specified condition, including Exposure via partner, Skin and Curling Ulcer. The degree of dosage is indicated in the table beneath, contingent upon the approach of delivery (e.g. Capsule or Vaginal).

Condition

Dosage

Administration

Vulvovaginitis

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Kit, Suppository, Suppository - Vaginal, Cream - Vaginal, Tablet, extended release - Oral, Tablet, extended release, Tablet, film coated - Oral, Tablet, film coated, Suppository - Rectal, Rectal, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, extended release, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Solution - Intravenous, Tablet, film coated, extended release - Oral, Injection - Intravenous, Kit - Oral

Tubo-ovarian abscess

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Kit, Suppository, Suppository - Vaginal, Cream - Vaginal, Tablet, extended release - Oral, Tablet, extended release, Tablet, film coated - Oral, Tablet, film coated, Suppository - Rectal, Rectal, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, extended release, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Solution - Intravenous, Tablet, film coated, extended release - Oral, Injection - Intravenous, Kit - Oral

Uterine Cervicitis

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Kit, Suppository, Suppository - Vaginal, Cream - Vaginal, Tablet, extended release - Oral, Tablet, extended release, Tablet, film coated - Oral, Tablet, film coated, Suppository - Rectal, Rectal, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, extended release, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Solution - Intravenous, Tablet, film coated, extended release - Oral, Injection - Intravenous, Kit - Oral

Giardiasis

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Kit, Suppository, Suppository - Vaginal, Cream - Vaginal, Tablet, extended release - Oral, Tablet, extended release, Tablet, film coated - Oral, Tablet, film coated, Suppository - Rectal, Rectal, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, extended release, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Solution - Intravenous, Tablet, film coated, extended release - Oral, Injection - Intravenous, Kit - Oral

Bacterial Peritonitis

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Kit, Suppository, Suppository - Vaginal, Cream - Vaginal, Tablet, extended release - Oral, Tablet, extended release, Tablet, film coated - Oral, Tablet, film coated, Suppository - Rectal, Rectal, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, extended release, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Solution - Intravenous, Tablet, film coated, extended release - Oral, Injection - Intravenous, Kit - Oral

Vaginitis

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Kit, Suppository, Suppository - Vaginal, Cream - Vaginal, Tablet, extended release - Oral, Tablet, extended release, Tablet, film coated - Oral, Tablet, film coated, Suppository - Rectal, Rectal, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, extended release, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Solution - Intravenous, Tablet, film coated, extended release - Oral, Injection - Intravenous, Kit - Oral

Bacterial Septicemia

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Kit, Suppository, Suppository - Vaginal, Cream - Vaginal, Tablet, extended release - Oral, Tablet, extended release, Tablet, film coated - Oral, Tablet, film coated, Suppository - Rectal, Rectal, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, extended release, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Solution - Intravenous, Tablet, film coated, extended release - Oral, Injection - Intravenous, Kit - Oral

Candida albicans

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Kit, Suppository, Suppository - Vaginal, Cream - Vaginal, Tablet, extended release - Oral, Tablet, extended release, Tablet, film coated - Oral, Tablet, film coated, Suppository - Rectal, Rectal, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, extended release, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Solution - Intravenous, Tablet, film coated, extended release - Oral, Injection - Intravenous, Kit - Oral

Pouchitis

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Kit, Suppository, Suppository - Vaginal, Cream - Vaginal, Tablet, extended release - Oral, Tablet, extended release, Tablet, film coated - Oral, Tablet, film coated, Suppository - Rectal, Rectal, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, extended release, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Solution - Intravenous, Tablet, film coated, extended release - Oral, Injection - Intravenous, Kit - Oral

Trichomonas Vaginitis

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Kit, Suppository, Suppository - Vaginal, Cream - Vaginal, Tablet, extended release - Oral, Tablet, extended release, Tablet, film coated - Oral, Tablet, film coated, Suppository - Rectal, Rectal, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, extended release, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Solution - Intravenous, Tablet, film coated, extended release - Oral, Injection - Intravenous, Kit - Oral

Communicable Diseases

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Kit, Suppository, Suppository - Vaginal, Cream - Vaginal, Tablet, extended release - Oral, Tablet, extended release, Tablet, film coated - Oral, Tablet, film coated, Suppository - Rectal, Rectal, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, extended release, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Solution - Intravenous, Tablet, film coated, extended release - Oral, Injection - Intravenous, Kit - Oral

Inflammatory Papule

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Kit, Suppository, Suppository - Vaginal, Cream - Vaginal, Tablet, extended release - Oral, Tablet, extended release, Tablet, film coated - Oral, Tablet, film coated, Suppository - Rectal, Rectal, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, extended release, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Solution - Intravenous, Tablet, film coated, extended release - Oral, Injection - Intravenous, Kit - Oral

Bacterial Vaginosis

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Kit, Suppository, Suppository - Vaginal, Cream - Vaginal, Tablet, extended release - Oral, Tablet, extended release, Tablet, film coated - Oral, Tablet, film coated, Suppository - Rectal, Rectal, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, extended release, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Solution - Intravenous, Tablet, film coated, extended release - Oral, Injection - Intravenous, Kit - Oral

Exposure via partner

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Kit, Suppository, Suppository - Vaginal, Cream - Vaginal, Tablet, extended release - Oral, Tablet, extended release, Tablet, film coated - Oral, Tablet, film coated, Suppository - Rectal, Rectal, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, extended release, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Solution - Intravenous, Tablet, film coated, extended release - Oral, Injection - Intravenous, Kit - Oral

post-surgical vaginal cuff infection

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Kit, Suppository, Suppository - Vaginal, Cream - Vaginal, Tablet, extended release - Oral, Tablet, extended release, Tablet, film coated - Oral, Tablet, film coated, Suppository - Rectal, Rectal, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, extended release, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Solution - Intravenous, Tablet, film coated, extended release - Oral, Injection - Intravenous, Kit - Oral

Bacterial Meningitis

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Kit, Suppository, Suppository - Vaginal, Cream - Vaginal, Tablet, extended release - Oral, Tablet, extended release, Tablet, film coated - Oral, Tablet, film coated, Suppository - Rectal, Rectal, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, extended release, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Solution - Intravenous, Tablet, film coated, extended release - Oral, Injection - Intravenous, Kit - Oral

Sinusitis

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Kit, Suppository, Suppository - Vaginal, Cream - Vaginal, Tablet, extended release - Oral, Tablet, extended release, Tablet, film coated - Oral, Tablet, film coated, Suppository - Rectal, Rectal, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, extended release, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Solution - Intravenous, Tablet, film coated, extended release - Oral, Injection - Intravenous, Kit - Oral

Endocarditis, Bacterial

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Kit, Suppository, Suppository - Vaginal, Cream - Vaginal, Tablet, extended release - Oral, Tablet, extended release, Tablet, film coated - Oral, Tablet, film coated, Suppository - Rectal, Rectal, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, extended release, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Solution - Intravenous, Tablet, film coated, extended release - Oral, Injection - Intravenous, Kit - Oral

Operative Surgical Procedures

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Kit, Suppository, Suppository - Vaginal, Cream - Vaginal, Tablet, extended release - Oral, Tablet, extended release, Tablet, film coated - Oral, Tablet, film coated, Suppository - Rectal, Rectal, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, extended release, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Solution - Intravenous, Tablet, film coated, extended release - Oral, Injection - Intravenous, Kit - Oral

Lockjaw

5.0 mg/mL, , 0.0075 mg/mg, 500.0 mg, 0.01 mg/mg, 7.5 mg/mL, 250.0 mg, 375.0 mg, 0.065 mg/mg, 125.0 mg, 10.0 %, 0.75 %, 1.0 %, 750.0 mg, 0.001 mg/mg, 200.0 mg, 400.0 mg, 100.0 mg/mL, 0.013 mg/mg, 0.5 mg/mg

Injection, solution, Injection, solution - Intravenous, Intravenous, , Gel - Topical, Topical, Gel, Oral, Tablet, Cream, Cream - Topical, Tablet - Oral, Lotion - Topical, Lotion, Capsule, Capsule - Oral, Vaginal, Gel - Vaginal, Kit, Suppository, Suppository - Vaginal, Cream - Vaginal, Tablet, extended release - Oral, Tablet, extended release, Tablet, film coated - Oral, Tablet, film coated, Suppository - Rectal, Rectal, Tablet, coated, Tablet, coated - Oral, Tablet, film coated, extended release, Ointment, Ointment - Topical, Insert - Vaginal, Insert, Solution, Solution - Intravenous, Tablet, film coated, extended release - Oral, Injection - Intravenous, Kit - Oral

Warnings

Nuvessa Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Metronidazole may interact with Pulse Frequency

Pregnancy Trimester, First

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Metronidazole may interact with Pulse Frequency

There are 20 known major drug interactions with Nuvessa.

Common Nuvessa Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The metabolism of Abemaciclib can be decreased when combined with Metronidazole.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be decreased when combined with Metronidazole.

Alectinib

Major

The metabolism of Alectinib can be decreased when combined with Metronidazole.

Alpelisib

Major

The metabolism of Alpelisib can be decreased when combined with Metronidazole.

Aminophylline

Major

The metabolism of Aminophylline can be decreased when combined with Metronidazole.

Nuvessa Toxicity & Overdose Risk

The maximum toxic dose of metronidazole in rats is 5000mg/kg. Symptoms of an overdose include nerve damage, poisoning of the central nervous system, seizures, feeling sick after drinking alcohol, dark urine, a metallic taste in the mouth, nausea, stomach discomfort, dizziness, and low white blood cell count. There is no specific treatment for an overdose and treatment should involve providing supportive care and giving activated charcoal to help remove the unabsorbed drug from the digestive system. Contact the local poison control center for more information on how to manage a metronidazole overdose.

Nuvessa Novel Uses: Which Conditions Have a Clinical Trial Featuring Nuvessa?

179 active studies are being conducted to evaluate the potential of Nuvessa in treating Curling Ulcer, Periodontitis and Central Nervous System Bacterial Infections.

Condition

Clinical Trials

Trial Phases

Lockjaw

0 Actively Recruiting

Uterine Cervical Erosion

0 Actively Recruiting

Gum Disease

2 Actively Recruiting

Not Applicable

Abdominal Infection

0 Actively Recruiting

Rosacea

0 Actively Recruiting

Balantidiasis

0 Actively Recruiting

Empyema

1 Actively Recruiting

Phase 4

Abdominal Abscess

2 Actively Recruiting

Phase 4, Phase 1, Phase 2

Bacteria

0 Actively Recruiting

Trichomonas Infections

0 Actively Recruiting

Vulvovaginitis

0 Actively Recruiting

Lung Abscess

0 Actively Recruiting

Pouchitis

5 Actively Recruiting

Early Phase 1, Phase 4, Phase 2

Atopic Dermatitis

16 Actively Recruiting

Phase 2, Phase 3, Not Applicable, Phase 4, Phase 1

Acne Vulgaris

0 Actively Recruiting

Operative Surgical Procedures

0 Actively Recruiting

Liver Abscess, Amebic

0 Actively Recruiting

Trichomonas Vaginitis

2 Actively Recruiting

Phase 2, Phase 4

Amebic colitis

0 Actively Recruiting

Rosacea

3 Actively Recruiting

Early Phase 1, Phase 2, Not Applicable

Nuvessa Reviews: What are patients saying about Nuvessa?

3

Patient Review

3/16/2020

Nuvessa for Vaginosis caused by Bacteria

I had been struggling with BV for over a year when I was finally prescribed Nuvaessa. It worked great at first, and kept the infection away for three months! However, my body seems to have built up a tolerance to the medication because it now comes back much sooner after taking Nuvaessa.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about nuvessa

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Nuvessa used for?

"NUVESSA® is a prescription medicine that is used to treat bacterial vaginal infections in females who are at least 12 years old. The safety and effectiveness of NUVESSA® in female children who are younger than 12 years old has not been determined."

Answered by AI

Is Nuvessa the same as metronidazole?

"NUVESSA is an aqueous gel that contains 1.3% metronidazole. The gel is formulated to have a pH of 4.0. The gel also contains benzyl alcohol, methylparaben, polycarbophil, polyethylene glycol 400, propylene glycol, propylparaben, and purified water."

Answered by AI

How effective is Nuvessa?

"The rest of the reviewers reported no change.

Nuvessa has an average rating of 6.8 from 8 reviews for the treatment of Bacterial Vaginosis. 25% of reviewers said it was effective, while 13% said it was not effective. The rest of the reviewers reported no change."

Answered by AI

How often can I use Nuvessa?

"Nuvessa may be used as a single dose, or for up to 5 nights in a row as needed."

Answered by AI

Clinical Trials for Nuvessa

Image of Boise VA Medical Center in Boise, United States.

Pharmacist-Led E-Consults for Lung Health in HIV

18+
All Sexes
Boise, ID

People with HIV (PWH) continue to experience elevated risk of community-acquired pneumonia despite effective antiretroviral therapy. Pneumonia contributes to hospitalization, respiratory failure, cardiovascular complications, long-term decline in lung function, and mortality. Several modifiable factors increase this risk, including active smoking, inadequate receipt of respiratory vaccinations, and inappropriate or prolonged use of inhaled corticosteroids (ICS) or proton-pump inhibitors (PPIs). OPTIMIZE Lung-HIV is a multicenter, patient-level randomized controlled hybrid Type 1 effectiveness-implementation trial evaluating whether a proactive, pharmacist-led E-consult intervention can improve evidence-based pulmonary pharmacotherapy for PWH. Pharmacists will review electronic health records, generate tailored recommendations, and pre-enter orders related to smoking cessation pharmacotherapy, vaccinations, and deprescribing of ICS or PPIs. Providers may enact or modify recommendations as clinically appropriate. The trial will assess the proportion of recommendations enacted within 3 months (primary outcome) and at 12 months (maintenance) and will use mixed methods guided by CFIR and RE-AIM to evaluate adoption, feasibility, acceptability, and implementation barriers and facilitators.

Waitlist Available
Has No Placebo

Boise VA Medical Center (+2 Sites)

Kristina A. Crothers, MD

Have you considered Nuvessa clinical trials?

We made a collection of clinical trials featuring Nuvessa, we think they might fit your search criteria.
Go to Trials
Image of San Francisco VA Medical Center in San Francisco, United States.

Dietary Salt for Eczema

18+
All Sexes
San Francisco, CA

The goal of this clinical trial is to evaluate the feasibility of low-sodium diet to improve eczema severity. The main questions it aims to answer are: * Does a low-sodium diet improve eczema severity? * How does a low-sodium diet impact skin sodium concentration? * Is skin sodium concentration associated with eczema severity? Researchers will ask all participant to follow a low-sodium diet, then compare sodium tablets to a placebo (a look-alike substance that contains no drug) to specifically examine the impact of altering sodium intake. Participants will: * Follow a low-salt diet for the duration of the 24-week study * Take sodium chloride tablets every day for 5 weeks followed by a placebo every day for 5 weeks after a 2-week washout period, or vice versa * Complete up to 4 virtual check-in visits * Visit the clinic 4 times to answer questionnaires, provide bio samples, complete dietary recalls, and undergo non-contrast sodium MRI

Phase 4
Waitlist Available

San Francisco VA Medical Center (+1 Sites)

Katrina Abuabara, MD

Image of Corvus Clinical Trials in South San Francisco, United States.

Soquelitinib for Eczema

18+
All Sexes
South San Francisco, CA

The main purpose of this study is to see how well different doses of soquelitinib work in participants with atopic dermatitis (AD) as compared to a placebo (pill with no medicine in it). To check this, the study doctors will examine participants' skin regularly to track how their AD changes during the study. The study doctors will see how safe soquelitinib is by tracking side effects among participants. They will also check "tolerability," which means how well the participants can handle soquelitinib and whether any potential side effects are manageable for them. To understand how well soquelitinib works, it will be compared with a placebo. Placebo is a substance that looks like soquelitinib but contains no active medicine in it. Participants will: * Take study treatment (soquelitinib or placebo) every day for 12 weeks * Visit the clinic for check-ups and tests every week for the first 2 weeks then every 2 weeks during the treatment period, and then return for follow-up visits 30, 60, and 90 days after the last dose of study treatment

Phase 2
Recruiting

Corvus Clinical Trials

Isin Sinem Bagci, MD

Corvus Pharmaceuticals, Inc.

Image of ALS Global in Irving, United States.

GX-03 for Eczema

18 - 80
All Sexes
Irving, TX

This is a Phase 2, randomized, double-blind, vehicle-controlled clinical study evaluating the efficacy and safety of GX-03 topical ointment in adult subjects with moderate to severe atopic dermatitis (eczema). The study plans to enroll up to 120 eligible patients with a target of at least 100 completing the study and an ability to expand enrollment up to 200 subjects based on a pre-specified interim assessment conducted by an Independent Data Monitoring Committee (IDMC). Subjects will be randomized in a 1:1 ratio to receive either GX-03 or vehicle control for 8 weeks. The study is designed to evaluate improvement in investigator-assessed disease severity, itch, and patient-reported eczema symptoms following topical treatment with GX-03 compared with vehicle control. Efficacy assessments include the Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-ADâ„¢), Eczema Area and Severity Index (EASI), Peak Pruritus Numeric Rating Scale (PP-NRS), and Patient-Oriented Eczema Measure (POEM). An interim assessment of conditional power for the primary efficacy endpoint will occur after the first 50 subjects complete the Week 8 visit or withdraw prematurely. Based on pre-specified criteria defined in the IDMC Charter, the IDMC may recommend continuation as planned, expansion of enrollment up to 200 subjects, or early curtailment of enrollment.

Phase 2
Recruiting

ALS Global

Turn Therapeutics

Have you considered Nuvessa clinical trials?

We made a collection of clinical trials featuring Nuvessa, we think they might fit your search criteria.
Go to Trials
Image of Children's of Alabama in Birmingham, United States.

Antibiotic Duration for Infections in Children

60 - 17
All Sexes
Birmingham, AL

Infections like pneumonia, skin and soft tissue infection (also called SSTI or cellulitis), and urinary tract infections (UTI) are some of the most common reasons children get admitted to the hospital. All three of these conditions require antibiotics for treatment. Although antibiotics are needed to treat the infection and help children feel better, taking them longer than needed can negatively impact children and their families. Negative impacts include things like the burdens of taking more medications and medication side effects. There are guidelines (instructions) from expert medical organizations that suggest the number of days children need antibiotics, but they give a wide range (between 5 and 14 days). Unfortunately, these guidelines are not based on high-quality studies. National data suggests that doctors often choose on the higher end of this range when writing prescriptions for children in the hospital. Our three caregiver co-investigators, other parents of hospitalized children, doctors, other care providers, and researchers, all believe that additional study is needed to determine the best length of antibiotic treatment that weighs both the benefits and harms of antibiotics. The goal of our study is to understand if 5 total days of antibiotic treatment compared to 10 total days of antibiotic treatment is better for children who have been in the hospital for pneumonia, SSTI, or UTI. We will study this question through a randomized control trial. In other words, half of the children will receive 5-days of antibiotics and the other half will receive 10-days of antibiotics. Children in this study (and their caregivers) will not know how many days of antibiotics they will receive to cure their infection because some children will take a placebo (or a pill without antibiotics in it). Only the pharmacy will know if a child is getting antibiotic or placebo (for days 6-10 of treatment). During the first phase of the trial (feasibility phase), 4 hospitals will enroll children in the study. We plan on enrolling 50 patients during this phase. We are starting with just 4 hospitals, so our study team can create and update our study plans if needed. We will closely review information about how many patients and families agree to participate, and if they have any trouble completing any part of the study. We will also interview families to understand the choice to participate in the study, the choice not to participate in the study, and what it is like to be in the study. During the second study phase, we will enroll 1150 more patients across all 11 hospitals. Families will complete short, daily surveys until the 15th day after they started antibiotics, then a larger survey at day 15, at day 20, and at day 30. These surveys will ask about the child's symptoms and recovery from their illness, how the antibiotics are making them feel, and if they had to go back to their doctor, emergency room, or hospital. The answers to these questions will be combined to measure how well the child did, balancing feeling better and having bad effects from the antibiotics. We will use mathematical tests to determine which antibiotic duration is better for treating these illnesses. We will complete other mathematical tests to see if all children should receive the same length of antibiotics or if certain children should be prescribed shorter courses and others longer courses.

Phase 4
Waitlist Available

Children's of Alabama (+9 Sites)

Sunitha V Kaiser, MD, MSc

Have you considered Nuvessa clinical trials?

We made a collection of clinical trials featuring Nuvessa, we think they might fit your search criteria.
Go to Trials